- 4-Week Delivery: World’s fastest custom mouse model development.
- TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
- Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
- Validated Quality: Guaranteed high precision and model viability.
Humanized GCGR Mouse Model
| Strain Name | Humanized GCGR Mouse Model (M60028) |
|---|---|
| Editing Type | Humanized |
| Gene Name | Gcgr (mouse glucagon receptor) |
| Gene Synonyms | GR |
| Strain Background | C57BL/6N |
| NCBI No. | Gene ID: 14527 / MGI:99572 |

1. Type 2 diabetes and metabolic disease Simulating the physiological and pathological function of human glucagon receptor (GCGR) to study its regulatory roles in glucose homeostasis, hepatic glycogenolysis, fatty acid metabolism and energy balance, and to build metabolic disease models closer to human disease.
2. GCGR-targeted drug evaluation Assessing the pharmacodynamics, pharmacokinetics and safety of antibodies, peptides and small-molecule antagonists or agonists targeting human GCGR in vivo, providing a preclinical platform for novel glucose-lowering agents and for drugs against non-alcoholic steatohepatitis (NASH).
3. Glucagon signaling pathway Within a fully humanized receptor background, dissecting the glucagon–GCGR axis in liver, pancreas, kidney and the central nervous system, and its crosstalk with other hormonal pathways such as insulin.
This mouse strain is generated by genetic engineering, replacing the coding region of the endogenous mouse glucagon receptor (Gcgr) gene with the human GCGR sequence. Retaining the endogenous mouse regulatory elements, the model expresses functional human GCGR protein in physiologically relevant cells and tissues, primarily the liver but also including the pancreas and kidneys. Glucagon binds and activates GCGR to maintain blood glucose homeostasis and drive hepatic glycogenolysis and gluconeogenesis, making the receptor an important therapeutic target for metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease (NAFLD/NASH). The humanized model allows candidate drugs targeting human GCGR — monoclonal antibodies, antagonists — to be evaluated for function, efficacy and safety in immunocompetent mice, overcoming the translation gap caused by receptor species differences in conventional models and markedly improving the predictive value of preclinical studies.
- The receptor a human drug actually binds. Antibodies and peptides raised against human GCGR frequently do not recognize the mouse receptor; here the target is human, so affinity and pharmacology transfer instead of being extrapolated.
- Mouse regulation kept. The coding region is swapped while endogenous regulatory elements stay in place, so expression follows the mouse’s own tissue pattern rather than a foreign promoter.
- Immunocompetent, unlike xenograft models. Efficacy and safety are read in an animal with an intact immune system — which is what antibody therapeutics actually require.
- A liver-dominant target with hard numbers. Adult liver RPKM 145.3 against near-background elsewhere: the receptor sits where glucagon actually acts, so hepatic readouts are physiologically placed.
- Both directions of pharmacology. Antagonists and agonists can both be tested — glucose lowering on one side, Mahvash-type loss-of-function biology on the other.

FAQ
Game-changing benefits?
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.
